Extracorporeal CO2 Removal Devices Market - Global Forecast 2025-2032

The extracorporeal CO2 removal devices market is experiencing steady advancement, driven by increased demand for innovative respiratory care solutions and the ongoing refinement of critical care technologies. Senior decision-makers are witnessing a shift in both clinical practice and procurement, as next-generation systems redefine patient management and supply chain resilience.

Market Snapshot: Extracorporeal CO2 Removal Devices

The extracorporeal CO2 removal devices market grew from USD 147.55 million in 2024 to USD 159.68 million in 2025. It is expected to continue growing at a CAGR of 8.67%, reaching USD 287.05 million by 2032. Accelerated trajectory is fueled by the integration of advanced device architectures and evolving regulatory frameworks. Market participants are balancing expanded clinical adoption with the practical complexities introduced by global trade policies.

Scope & Segmentation

This research report provides in-depth analysis and forecasts across all major dimensions of the market. Strategic segmentation and coverage include:

• Product Types: ECCO2R machines, membrane oxygenators, roller pumps
• Access: Arteriovenous, venovenous
• Mode of Operation: Automated systems, manual systems
• Application: Acute respiratory distress syndrome, bridge to lung transplant, chronic obstructive pulmonary disease
• End User: Ambulatory surgical centers, home care settings, hospitals, specialty clinics
• Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Companies Covered: Aferetica Srl, ALung Technologies, Inc. by LivaNova PLC, Baxter International Inc., Drägerwerk AG & Co. KGaA, Edwards Lifesciences Corporation, Estor S.p.A, Fresenius Medical Care AG, Getinge AB, Inspira-Technologies OXY B.H.N. LTD, Koninklijke Philips N.V., LivaNova PLC, Medica S.p.A, MicroPort Scientific Corporation, Nikkiso Co., Ltd., NovaLung GmbH, Terumo Corporation, X-COR Therapeutics, XENIOS AG by Fresenius Medical Care AG & Co. KGaA

Key Takeaways for Senior Decision-Makers

• Evolving device platforms now prioritize compactness, integration with existing support systems, and operational efficiency, supporting broader adoption in diverse clinical environments.
• Clinical evidence continues to expand, enhancing confidence among care teams and shifting utilization from salvage therapy toward elective and chronic management pathways.
• Manufacturers are responding to growing regulatory and reimbursement complexity by forming strategic alliances, pursuing modular design, and investing in data-driven clinical validation initiatives.
• Regional procurement trends reveal that hospitals adopt consortium models for standardized protocols, while emerging markets seek cost-optimized entry-level solutions.
• Supplier investments in real-time sensor integration and predictive analytics are elevating standards for patient monitoring, while modular architectures improve both user training and product customization.

Tariff Impact on Global Supply Chains

Impending United States tariffs on critical care device components are driving manufacturers to reconfigure their supply networks. Key production processes are shifting toward regional hubs to reduce exposure to import duties, prompting a reassessment of sourcing and vendor strategies. Contract negotiations and long-term agreements are becoming vital as stakeholders seek stability in procurement and pricing. Hospitals and clinics are leveraging group purchasing to optimize financial outcomes, while domestic innovation in material science is encouraged to reinforce ecosystem resilience.

Extracorporeal CO2 Removal Devices Market: Methodology & Data Sources

The market analysis merges insights from primary interviews with clinicians, engineers, and industry experts, combined with a review of regulatory filings and corporate disclosures. Qualitative and quantitative data have been synthesized from peer-reviewed literature, policy documents, and real-world case studies to clarify usage patterns, technological trends, and entrenchment challenges.

Why This Report Matters

• Supports informed capital allocation and strategic planning by presenting a clear view of evolving market demands and clinical adoption drivers.
• Enables stakeholders to benchmark against competitive trends, regulatory shifts, and operational best practices across global regions.

Primary Keyword: Extracorporeal CO2 Removal Devices Market

This report delivers actionable intelligence to guide device portfolio development, supply chain adaptation, and stakeholder partnership models in the extracorporeal CO2 removal devices market landscape.

Conclusion

As the field progresses toward routine implementation in critical care, aligning product innovation, resilient sourcing, and collaborative engagement will be vital for sustained market leadership. This report serves as the foundation for data-driven decision-making in an evolving therapeutic landscape.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.